Last reviewed · How we verify
original sevoflurane
Sevoflurane is a volatile anesthetic that enhances inhibitory neurotransmission and suppresses excitatory neurotransmission in the central nervous system to produce anesthesia.
Sevoflurane is a volatile anesthetic that enhances inhibitory neurotransmission and suppresses excitatory neurotransmission in the central nervous system to produce anesthesia. Used for General anesthesia for induction and maintenance during surgery, Anesthesia in pediatric and adult patients.
At a glance
| Generic name | original sevoflurane |
|---|---|
| Also known as | Sevorane® (Abott Korea Ltd, Seoul, Korea) |
| Sponsor | Asan Medical Center |
| Drug class | Volatile anesthetic |
| Target | GABA-A receptor, NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | FDA-approved |
Mechanism of action
Sevoflurane acts primarily as a positive allosteric modulator of GABA-A receptors and an antagonist of NMDA receptors, leading to depression of the central nervous system. This results in loss of consciousness, amnesia, and analgesia suitable for general anesthesia during surgical procedures. The drug is rapidly absorbed and eliminated via the lungs, allowing for quick induction and recovery.
Approved indications
- General anesthesia for induction and maintenance during surgery
- Anesthesia in pediatric and adult patients
Common side effects
- Postoperative nausea and vomiting
- Emergence delirium
- Airway irritation
- Hypotension
- Bradycardia
Key clinical trials
- Pharmacokinetics of Sufentanil After Epidural Administration
- Modern Myorelaxation Procedure and Reversal of Neuromuscular Blockade With General Anesthesia for Caesarean Section (PHASE4)
- Long Term Postoperative Cognitive Dysfunction in the Elderly Patients (PHASE4)
- Efficacy and Safety of Sevofran in Patients Scheduled for Elective Surgery Under General Anesthesia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- original sevoflurane CI brief — competitive landscape report
- original sevoflurane updates RSS · CI watch RSS
- Asan Medical Center portfolio CI